Literature DB >> 22642767

A new prognostic classification for overall survival in Asian patients with previously untreated metastatic renal cell carcinoma.

Nobuo Shinohara1, Katsuya Nonomura, Takashige Abe, Satoru Maruyama, Takao Kamai, Masayuki Takahashi, Katsunori Tatsugami, Shigeaki Yokoi, Takashi Deguchi, Hiroomi Kanayama, Koji Oba, Seiji Naito.   

Abstract

The aims of the present study were to: (i) develop a clinically useful prognostic classification in Asian patients with metastatic renal cell carcinoma (RCC) by combining metastatic features with several pretreatment parameters; and (ii) evaluate the validity of this prognostic classification. Baseline characteristics and outcomes were collected for 361 patients who underwent interferon-α-based therapy between 1995 and 2005. Relationships between overall survival (OS) and potential prognostic factors were assessed using Cox's proportional hazard model. The predictive performance of the model was evaluated using bootstrap resampling procedures and by using an independent dataset obtained from randomly selected institutions. The predictive accuracy was measured using the concordance index (c-index). Four factors were identified as independent prognostic factors: time from initial diagnosis to treatment, anemia, elevated lactate dehydrogenase (LDH), and poor prognostic metastatic group (liver only, bone only, or multiple organ metastases). Each patient was assigned to one of three risk groups: favorable risk (none or one factor; n = 120), in which median OS was 51 months; intermediate risk (two factors; n = 101), in which median OS was 21 months; and poor risk (three or four factors; n = 102), in which median OS was 10 months. The c-index was 0.72 in the original dataset and 0.72 in 500 random bootstrap samples. In the independent dataset for external validation, the c-index was 0.73. Thus, the new prognostic classification is easily applicable for Asian patients with previously untreated metastatic RCC and should be incorporated into patient care, as well as clinical trials performed in Asia.
© 2012 Japanese Cancer Association.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22642767     DOI: 10.1111/j.1349-7006.2012.02351.x

Source DB:  PubMed          Journal:  Cancer Sci        ISSN: 1347-9032            Impact factor:   6.716


  18 in total

1.  Oncological outcomes classified according to metastatic lesions in the era of molecular targeted drugs for metastatic renal cancer.

Authors:  Yasuomi Shimizu; Taro Iguchi; Satoshi Tamada; Sayaka Yasuda; Minoru Kato; Noriko Ninomiya; Takeshi Yamasaki; Tatsuya Nakatani
Journal:  Mol Clin Oncol       Date:  2018-04-24

2.  Development of a realistic in vivo bone metastasis model of human renal cell carcinoma.

Authors:  Maija P Valta; Hongjuan Zhao; Alexandre Ingels; Alan E Thong; Rosalie Nolley; Matthias Saar; Donna M Peehl
Journal:  Clin Exp Metastasis       Date:  2014-04-09       Impact factor: 5.150

3.  Prognostic role of interleukin-6 in renal cell carcinoma: a meta-analysis.

Authors:  Y Wang; Y Zhang
Journal:  Clin Transl Oncol       Date:  2019-08-13       Impact factor: 3.405

4.  Early primary renal tumor response predicts clinical outcome in patients with primary unresectable renal cell carcinoma with synchronous distant metastasis receiving molecularly targeted therapies.

Authors:  Kosuke Ueda; Shigetaka Suekane; Kiyoaki Nishihara; Hiroki Suekane; Naoyuki Ogasawara; Hirofumi Kurose; Katsuaki Chikui; Kazuhisa Ejima; Shunsuke Suyama; Makoto Nakiri; Mitsunori Matsuo; Tsukasa Igawa
Journal:  Mol Clin Oncol       Date:  2017-06-15

5.  Clinical characteristics and prognosis of patients with renal cell carcinoma and liver metastasis.

Authors:  Shinsuke Hamada; Keiichi Ito; Kenji Kuroda; Akinori Sato; Junichi Asakuma; Akio Horiguchi; Kenji Seguchi; Tomohiko Asano
Journal:  Mol Clin Oncol       Date:  2014-09-29

6.  Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era.

Authors:  Sei Naito; Tomoyuki Kato; Kazuyuki Numakura; Shingo Hatakeyama; Tomoyuki Koguchi; Shuya Kandori; Yoshihide Kawasaki; Hisanobu Adachi; Renpei Kato; Shintaro Narita; Hayato Yamamoto; Soichiro Ogawa; Sadafumi Kawamura; Wataru Obara; Akihiro Ito; Hiroyuki Nishiyama; Yoshiyuki Kojima; Chikara Ohyama; Tomonori Habuchi; Norihiko Tsuchiya
Journal:  Int J Clin Oncol       Date:  2021-06-30       Impact factor: 3.402

7.  Improvement of prognosis in patients with metastatic renal cell carcinoma and Memorial Sloan-Kettering Cancer Center intermediate risk features by modern strategy including molecular-targeted therapy in clinical practice.

Authors:  Tomomi Kamba; Toshinari Yamasaki; Satoshi Teramukai; Noboru Shibasaki; Ryuichiro Arakaki; Hiromasa Sakamoto; Yoshiyuki Matsui; Kazutoshi Okubo; Koji Yoshimura; Osamu Ogawa
Journal:  Int J Clin Oncol       Date:  2013-06-28       Impact factor: 3.402

8.  Upregulation of RICTOR gene transcription by the proinflammatory cytokines through NF-κB pathway contributes to the metastasis of renal cell carcinoma.

Authors:  Bo Sun; Liwei Chen; Hui Fu; Lin Guo; Hua Guo; Ning Zhang
Journal:  Tumour Biol       Date:  2015-10-25

9.  Prognosis of Japanese patients with previously untreated metastatic renal cell carcinoma in the era of molecular-targeted therapy.

Authors:  Nobuo Shinohara; Wataru Obara; Katsunori Tatsugami; Sei Naito; Tomomi Kamba; Masayuki Takahashi; Sachiyo Murai; Takashige Abe; Koji Oba; Seiji Naito
Journal:  Cancer Sci       Date:  2015-03-19       Impact factor: 6.716

10.  Clinical Characteristics and Prognosis of Renal Cell Carcinoma With Spinal Bone Metastases.

Authors:  Jianpo Zhai; Ning Liu; Hai Wang; Guanglin Huang; Libo Man
Journal:  Front Oncol       Date:  2021-06-16       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.